Compare DexCom, Inc. (DXCM) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI China ETF — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while iShares MSCI China ETF trades at $54.27. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | MCHI | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $66.99 |
52-Week Low | $54.84 | $50.48 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MCHI trades at $54.29, up 1.99% with a bullish technical signal from moving averages, though oscillators are neutral. The stock shows strong momentum near recent highs, supported by China's AI-driven factory rebound and export growth. Recent news highlights China's $295 billion AI infrastructure plan and robust trade data, though geopolitical tensions with the U.S. pose headwinds.
Outlook remains mixed: AI sector tailwinds and undervaluation offer upside, but structural risks and analyst skepticism suggest caution. Key risks include U.S.-China tech rivalry and domestic economic pressures. Institutional sentiment is divided, with some seeing value while others warn of a value trap.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
